Matt Call

Matthew joined iTeos Therapeutics in 2019 as Chief Operating Officer. He has nearly 20 years’ experience in business development and corporate strategy leadership roles in the biotech space. Prior to joining iTeos, Matt served as Chief Operating Officer at Endocyte, a Novartis company, leading all business functions. He led all strategic partnering and licensing activities resulting in numerous successful transactions, including Endocyte’s transformational in-license of PSMA-617, which led to the $2.1 billion acquisition of Endocyte by Novartis. Matt managed Endocyte’s billion-dollar out-licensing partnership with Merck and sat on the Joint Development and Joint Commercialization Committees. During his tenure at Endocyte, Matt also supervised new product planning, strategic planning, project management and marketing. Matt started his career in corporate strategy, business development and alliance management in the high tech space.